ISIuliia Andreevna Sorokina

Iuliia Andreevna Sorokina

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Iuliia Andreevna Sorokina has a total of 70 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Clinical observation of a patient with chronic COVID-19 and type 2 diabetes mellitus

    by S. A. Sukhanov, O. V. Zanozina, Yu. A. Sorokina, V. N. Lagonskaya, M. V. Kobalava, С. А. Суханов, О. В. Занозина, Ю. А. Сорокина, В. Н. Лагонская, М. В. Кобалава

    This article describes the clinical observation of the patient who developed multiple new diseases after suffering a new coronavirus infection in 2020. Before COVID-19, she had only been diagnosed with hypertension. The patient experienced a severe case of COVID-19, developing pneumonia (CT2) in 2020 (at age 52), Four months later, diabetes mellitus was newly diagnosed, and three months later bronchial asthma and paroxysmal arrhythmias were diagnosed . Three years later, in 2024, the patient again experienced a new coronavirus infection, after which she noted a significant deterioration in cognitive function, hypertension control, and diabetes. Over the past year, progression of all microand macrovascular complications of diabetes mellitus has been noted – nephropathy (decrease in SCF from 55 to 21 ml per min), retinopathy (non-proliferative retinopathy), significant deterioration of polyneuropathy, progression of atherosclerosis, confirmed by instrumental methods (ultrasound Doppler imaging of the lower extremities, ultrasound Doppler imaging of the cerebral vessels). The data are consistent with severe post-COVID syndrome. The results are compared with global data. Risk factors for the development of post-COVID syndrome are identified. Associations of single-nucleotide polymorphisms of pleotropic genes with the development of severe post-COVID syndrome are found. Personalized therapy is identified.

  • Open Access

    Genetic polymorphism of post-COVID syndrome in patients with type 2 diabetes mellitus

    by S. A. Sukhanov, O. V. Zanozina, Yu. A. Sorokina, V. N. Lagonskaya, M. V. Kobalava, С. А. Суханов, О. В. Занозина, Ю. А. Сорокина, В. Н. Лагонская, М. В. Кобалава

    The long-term consequences of COVID-19 remain poorly understood. All authors agree on one thing: single nucleotide polymorphisms (SNPs) have the potential to become a valuable tool for predicting long-term clinical outcome in patients infected with SARS-CoV-2. Thus, the ACE2 rs2106809 SNP has been shown to be a functional marker of brain changes, and its potential involvement in long-term COVID-19 requires further study. Recent studies have linked the FOXP4 gene to the severity of COVID-19 and the risk of long-term COVID-19. SNP rs9367106 is likely associated with the development of long-term symptomatic abnormalities in the lungs and brain observed after recovery from COVID-19. Olfactory and gustatory impairment has been identified as a pathognomonic feature not only of acute COVID-19 but also of post-COVID chronic fatigue syndrome, and is determined by the leading single nucleotide polymorphism rs10893121. Also, CC genotypes of the methylenetetrahydrofolate reductase (MTHFR) gene were statistically more common in chronic COVID-19. It can be assumed that some variants of nucleotide sequences involved in the genesis of diabetes and its complications, in the formation of patient comorbidity, and in the development of COVID, may potentially participate in the formation of PCS in patients with diabetes. We have demonstrated an association with post-COVID syndrome of single nucleotide polymorphisms in the following genes: FABP2, NOS3, COMT, and PAI-1. Subsequently, phenotypes of post-COVID syndrome will be developed in patients with type 2 diabetes, taking into account genetic determinants. A prognosis for the post-COVID period in this category of patients will be determined. Consequently, personalized treatment for patients will be developed, taking into account the combination of pathological alleles of pleiotropic genes.

  • Significance of certain leukocyte indices in patients with type 2 diabetes who have had novel coronavirus infection

    by S. A. Sukhanov, Yu. A. Sorokina, O. V. Zanozina, A. A. Mosinа, I. D. Kapranova

    Сhronic low-intensity inflammation is the one of the mechanisms of development of diabetes mellitus type 2. In order to objectify this process, some leukocyte indices are used (the ratio of neutrophils to lymphocytes – NLR, the ratio of platelets to lymphocytes – PLR, the ratio of lymphocytes to monocytes – LMR, the ratio of monocytes to lymphocytes – MLR, as well as the index of systemic immune inflammation SII (calculated taking into account neutrophils, lymphocytes, platelets), taking into account the presence of both microvascular and macrovascular late complications in patients with diabetes mellitus. The new coronavirus infection significantly increases the inflammation process that’s why some leukocyte indices are to be prognostic markers of the disease outcomes. The article presents the latest data on the significance of inflammation markers in multimorbid patients with a new coronavirus infection. It is emphasized that data on the study of leukocyte indices in patients with diabetes mellitus who have had a new coronavirus infection are scarce, and information on the use of such a simple tool for studying inflammation as leukocyte indices in assessing post-COVID disorders in patients with diabetes mellitus is absent. Our data concluded that the learning information about inflammation in patients with type 2 diabetes and post-COVID syndrome using leukocyte indices is really promising.


  • Open Access

    The Influence of Gut Microbiota on the Development of Schizophrenia. Ways of Pharmacologic Correction (Systematic Scoping Review)

    by Лилия Хайдяровна Абдуллина, Анна Алексеевна Мосина, Yulia A. Sorokina, Елена Петровна Струева

    Влияние микробиоты кишечника на развитие шизофрении. Пути фармакологической коррекции (систематический обзор предметного поля)

  • Open Access

    The use of hypolipidemic agents in patients with hyperuricemia on the background of type 2 diabetes mellitus and atherosclerosis

    by A. A. Mosina, Yu. A. Sorokina, L. V. Lovtsova, A. L. Urakov

    Diabetes mellitus (DM) is one of the most common pathologies today. According to the Federal Register of Diabetes Mellitus, the number of patients increases by about 5% every year. As a rule, the medical history is complicated by the presence of other concomitant pathologies. And this applies not only to cardiovascular diseases, but also to lipid metabolism disorders (dyslipidemia, obesity, atherosclerosis), uric acid metabolism and excretion (hyperuricemia, gout). There was a clear correlation between complications of diabetes and atherosclerosis due to an increase in uric acid levels in blood plasma. This increase can occur for several reasons. Hereditary predisposition, consumption of foods with a high content of purine compounds and further violation of their excretion, adherence to strict diets, intense physical activity. Patients, as a rule, experience severe unbearable joint pain, swelling and redness of the skin at the site of the lesion. It should be noted that asymptomatic hyperuricemia appeared not so long ago, in which uric acid levels reach critical values without obvious clinical symptoms. Hyperuricemia is another aggravating factor for patients with type 2 diabetes. It is important that such patients are characterized by polyprogmasia. And here, special attention should be paid to the interaction of drugs and the identification of additional positive pharmacological effects on concomitant pathologies. It is known that drugs from the group of statins have multiple effects. That is why the study of the full range of pharmacological effects and their possible application in practical medicine remains one of the main tasks of pharmacotherapy.


  • Open Access

    Contemporary prospects for the use of sodium-glucose cotransporter-2 inhibitors

    by A. R. Kondratieva, E. A. Khazova, A. V. Lobanova, Yu. A. Sorokina, A. A. Mosina, O. V. Zanozina

    To determine contemporary prospects for the use of non-glycemic effects of sodium-glucose cotransporter-2 inhibitors in comorbid patients, the analysis of existing studies was carried out. The mechanisms of action of sodium-glucose cotransporter-2 inhibitors discovered during the EMPA-REG OUTCOME study which were previously unknown, encouraged further research on the use of these drugs in other pathological conditions. The authors of the article have analyzed some clinical and preclinical studies on the use of this drug group in such conditions as stroke, cancer, rheumatological diseases, and rhythm disorders, as well as their impact on the development of major adverse cardiovascular events. The effects of oxidative stress suppression in the myocardium and nervous tissue with an increase in the number of mitochondria which reduces the risk of developing rhythm disorders, improves neoangiogenesis in the focus of ischemic necrosis, and has neuroprotective effects are described in the article. In oncological diseases, gliflozins prevent proliferation of tumor cells and oncogenesis through the induction of late apoptosis and also have cardioprotective effects in patients undergoing chemotherapy. The use of these medicines reduces the incidence of major adverse cardiovascular events, as well as restenosis after intravascular interventions. The positive effect on the course of rheumatological diseases was in improving laboratory parameters in a number of diseases and reducing the frequency of exacerbations and visits to a doctor in patients with gout. With a constant increase in the number of patients with comorbid conditions, it is important to carry out further study of pleiotropic effects of sodium-glucose cotransporter-2 inhibitors for the subsequent introduction of new data into clinical practice.


  • Open Access

    Pathogenetic relationship of microbiome and metabolic disorders on the background of hypertension and gout: Potential targets of pharmacotherapy

    by S. D. Sinyushkina, A. V. Gorinova, A. S. Belousova, Yu. A. Sorokina, O. V. Zanozina

    Cardiometabolic diseases are one of the urgent problems of modern medicine. Currently, much attention is being paid to the study of the common pathogenesis of diabetes mellitus, gout and hypertension. One of the pharmacological targets is the correction of the intestinal microbiome and dysbiosis, as an integral link in the development of systemic inflammation and endotoxinemia, leading to the development of these pathologies. The article presents the results of scientific research devoted to the study of the effect of the intestinal microbiome on the development of cardiometabolic diseases. The main goal of the research is to find a rational pharmacological therapy of intestinal dysbiosis for the treatment of comorbid patients. It has been proved that, together with standard drug therapy, taking into account the pathogenetic features of the development of cardiometabolic diseases, it is advisable to use drugs that affect the intestinal microbiome. The main classical approach is the use of probiotic drugs containing live bacteria. The use of probiotics in combination with probiotic drugs to support the growth of intestinal normoflora has become a promising direction. However, this approach requires a long period of correction of the microflora, which prompted the idea of using postbiotics – signaling molecules – products of the vital activity of the microflora for a more targeted and rapid effect on pathological processes, both in the intestine and on the organ system as a whole. This approach promotes the beginning of the development of synbiotics, a complex of microorganisms, growth factors and metabolites that made it possible to more effectively influence on dysbiotic processes in various pathologies, including dyslipidemia and cardiovascular diseases. Correction of intestinal barrier permeability disorders will help prevent the development of systemic complications associated with chronic pathologies. The article also presents the author’s scheme of the pathogenesis of cardiometabolic diseases, based on the study of current scientific research.

  • Open Access

    A smart device for smart self-monitoring of glycemia in patients with diabetes

    by O. V. Zanozina, Yu. A. Sorokina, N. Yu. Taradayko, S. A. Sukhanov, T. S. Aksenova, Н. Ю. Тарадайко

    Systemic vascular complications of diabetes mellitus (nephropathy, retinopathy, injuries to the great vessels of the heart, brain, arteries of the lower extremities) have been proven to lead to early disability and premature death of patients. The annual economic costs of T2DM and associated cardiovascular complications account for at least 1% of GDP. According to the principles of therapeutic management of diabetes mellitus, patient education is viewed as an integrated component of the treatment process. It should provide patients with knowledge and skills that contribute to achieving specific therapeutic goals (disease self-management). Self-monitoring of blood glucose training is a priority objective in the treatment of patients with diabetes. It is self-monitoring of glycemia that is the most important criterion for selecting therapy, compared with the glycemia testing in an outpatient clinic or hospital settings. Modern glucometers provide an option for remote monitoring of glycemia and timely delivering of consultations using a mobile application. Thus, Contour Plus One glucometer with the Russian-language application Contour Diabitis records the blood glucose readings following each test. If low or high glycaemic levels are detected, the application will show a notification and offer the patient options for actions. Quick recognizing out-of-range lab results motivates patients and helps them understand why changes in therapy are required. Immediate notifications shown on the smartphone screen improve motivation to act and respond to the situation. The glucometer system with a mobile application allows to promptly manage glycemia, increase patient’s commitment to active disease management, achieve treatment goals using innovative technologies, and therefore actively manage the course of diabetes mellitus.


  • Open Access

    Post-COVID syndrome in patients with type 2 diabetes: definition, epidemiology, pathophysiology, biomarkers and genetic associations

    by S. A. Sukhanov, Yu. A. Sorokina, O. V. Zanozina

    The article presents the modern ideas about post-COVID syndrome, indicates various types and classifications of post-COVID syndrome, provides epidemiological data, including the patients with type 2 diabetes, also the definition of post-COVID syndrome is given. The group of patients defined as patients with post-COVID syndrome is very heterogeneous. Post-COVID syndrome is more common in the elderly, with comorbid pathology, severe disease. The pathophysiology of this syndrome in patients with type 2 diabetes mellitus is analyzed, and risk factors are indicated. The main biomarkers of disorders were determined: monocytes and their coefficients, acute phase proteins, some biochemical indicators, including analysis of genetic associations with the severity of post-COVID disorders (interferon gamma gene, methylenetetrahydrofolate reductase gene, ACE2 inhibitor). Genotyping of a sample of 26 single nucleotide polymorphisms in genes implicated in viral entry, immune response, and inflammation were significantly associated not only with the risk of long-term COVID-19 symptoms, but also with the cumulative incidence of post-COVID syndrome. Elevated levels of interleukin 6, C-reactive protein and tumor necrosis factor alpha may serve as potential diagnostic biomarkers in long-term COVID biomarkers of blood vascular transformation have great potential for diagnosis, and angiogenesis modulators may have therapeutic efficacy It has been shown that the vast majority of patients, in particular those suffering from type 2 diabetes, develop post-COVID-19 syndrome, and taking into account pre-existing diseases, post-COVID syndrome is not so harmless. By identifying common biomarkers and genetic associations, it is possible to identify the common molecular mechanism of post-COVID syndrome COVID-19 and diabetes mellitus. The novelty of disease association studies in the context of COVID-19 provides new insights into the management of rapidly evolving long-term COVID and post-COVID syndromes that have significant global implications.


  • Open Access

    Cardiovascular pathology and intestinal microbiome relationship: potential targets of pharmacotherapy

    by Y. A. Sorokina, N. A. Petunina, S. D. Sinyushkina, A. V. Gorinova, M. I. Pryazhnikova, S. A. Sukhanov, A. S. Rudakov, O. V. Zanozina

    Связь сердечно-сосудистой патологии и микробиома кишечника: потенциальные мишени фармакотерапии